Avenue Therapeutics Q2 EPS $(6.43) Misses $(1.05) Estimate
Portfolio Pulse from Benzinga Newsdesk
Avenue Therapeutics (NASDAQ:ATXI) reported a Q2 EPS of $(6.43), significantly missing the analyst consensus estimate of $(1.05) by 512.38%. This represents an 83.4% improvement over the $(38.74) per share loss from the same period last year.
August 09, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avenue Therapeutics reported a Q2 EPS of $(6.43), missing the analyst estimate of $(1.05) by a wide margin. Despite the miss, the loss is an improvement from the $(38.74) per share loss in the same period last year.
The significant miss on EPS estimates is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100